【摘要】 目的分析观察康莱特注射液联合多西他赛+奈达铂化疗治疗中晚期非小细胞肺癌(NSCLC)患者的疗效。方法将80例中晚期NSCLC患者按随机数字表法等比例分为对照组与观察组,每组40例。对照组予以多西他赛+奈达铂化疗治疗,观察组予以康莱特注射液联合多西他赛+奈达铂化疗治疗,比较两组患者的近期疗效、肿瘤相关细胞因子表达水平、卡氏功能状态(KPS)评分、不良反应发生情况以及无进展生存期(PFS)。结果治疗后,观察组患者总有效率、临床受益率均高于对照组(P<0.05);两组患者细胞角质蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原19-9(CA19-9)蛋白水平和血黏蛋白1(MUC1)mRNA表达水平均降低(P<0.05),磷酸酶张力蛋白同源物(PTEN)m RNA表达水平均升高(P<0.05),且观察组患者上述指标变化幅度更大(P<0.05)。治疗1、2个疗程后,两组患者KPS评分均升高(P<0.05),且观察组均高于对照组(P<0.05)。观察组患者骨髓抑制、胃肠道不良反应发生率均低于对照组,差异均有统计学意义(P<0.05)。观察组患者PFS为5.72个月(95%CI:5.13～6.34),长于对照组的4.01个月(95%CI:3.79～5.26),差异有统计学意义(P<0.05)。结论康莱特注射液联合多西他赛+奈达铂化疗治疗中晚期NSCLC患者,可明显提高近期疗效,调节肿瘤相关细胞因子表达水平,改善患者生活质量,降低不良反应发生率,控制疾病进展。更多还原

【Abstract】 Objective To analyze the efficacy of kanglaite injection combined with docetaxel + nedaplatin chemotherapy in patients with advanced non-small cell lung cancer(NSCLC). Method A total of 80 patients with advanced NSCLC were selected and divided into control group(n=40, treated with docetaxel + nedaplatin chemotherapy) and observation group(n=40, treated with kanglaite injection combined with docetaxel+nedaplatin chemotherapy) according to the random number table. The short-term efficacy, tumor-associated cytokine expression, Karnofsky performance status(KPS) score, occurrence of adverse reactions and progression-free survival(PFS) were compared between the two groups. Result After treatment, the total effective rate and clinical benefit rate in observation group were significantly higher than those in control group(P<0.05). The protein expression levels of cyto-keratin 19 fragment antigen 21-1(CYFRA21-1), carbohydrate antigen 19-9(CA19-9) and the mucin-1(MUC1) mRNA expression levels were significantly decreased in the two groups(P<0.05), the m RNA expression levels of phosphatase and tensin homolog(PTEN) were significantly increased in the two groups(P<0.05), and the above indexes changed more in the observation group(P<0.05). The KPS scores in the two groups were significantly increased at 1 course and 2 courses of treatment(P<0.05), and the scores of the observation group were higher than those of the control group(P<0.05). The incidence of myelosuppression and gastrointestinal reactions in observation group were significantly lower than those in control group(P<0.05). The PFS of the observation group was 5.72 months(95%CI: 5.13-6.34) longer than that of the control group for 4.01 months(95%CI:3.79-5.26), the difference was statistically significant(P<0.05). Conclusion Kanglaite injection combined with docetaxel + nedaplatin chemotherapy for patients with advanced NSCLC can significantly improve the short-term efficacy, regulate the expression levels of tumor-associated cytokines, improve the quality of life, reduce the adverse reactions, and control disease progression.更多还原